Recent trends highlight a surge in demand for mass market medicines. This increase is driven by lessons from the Covid-19 pandemic, when vaccines had to be made available quickly in large quantities, but also from the ongoing need for diabetes or weight loss medication. GMP-compliance, quality control, risk of contamination as well as cost of production and time to market are some of the increasingly significant challenges that companies delivering large batch sizes are confronted by.
Having a competent and efficient partner by your side, capable of addressing these challenges through top-notch integrated end-to-end solutions can elevate your mass production to new levels of efficiency and sustainable success. Here’s where the unique Körber Ecosystem approach comes into play – ensuring worldwide healthcare from the initial idea to the finished solution: with everything, effortlessly, in one place.
Highlights:
- What are the biggest challenges of pharma mass production?
- How to streamline your mass production and reduce complexity by leveraging the Körber Ecosystem approach?
- Which integrated end-to-end solutions does Körber offer?
In the dynamic landscape of the pharmaceutical industry, companies are continually grappling with opposing trends. On the one hand, there's a growing demand for individualized medicine and small batch sizes tailored to specific patient groups. On the other hand, the ageing of the world's population and the increase in obesity, for example, have led to a greater need for corresponding mass-market medication worldwide.
While some pharmaceutical companies are specialized in individualized medicine and therefore need to produce small, flexible batches, others focus on the large-scale production of mass market medicine. These companies must be able to scale their production to produce large volumes of products without compromising on efficiency, quality, and safety. Regulatory compliance then becomes more complex, and the risk of contamination or errors can increase. Furthermore, the cost of production can escalate quickly if not managed effectively. Time-to-market pressures necessitate rapid development and commercialization of new drugs and any delays in production can result in lost market share and revenue. Solving these pain points holistically enables fast production which can support the need for big batches. This is where we step in.